High-priority initiatives according to their impact and feasibility values
| Initiative | Impact | Mean feasibility |
| 4.4 Establish and share a working protocol on short-term prophylaxis, defining situations in which it should be carried out and the medication to be administered | 5 | 5 |
| 5.1 Have a reference pharmacist for the pathology and promote initiatives that reinforce the visibility of the hospital pharmacist to patients | 5 | 5 |
| 5.5 Conduct informative/training sessions with patients and other healthcare professionals on the management of HAE and medication | 5 | 5 |
| 5.6 Provide information/training (oral/written) to patients on safety issues, enabling them to acquire skills to detect adverse effects, tolerance and safety, as well as training them to ensure adherence | 5 | 5 |
| 4.1 Preparation of guidelines with recommendations for coordinating the multidisciplinary team responsible for managing patients with HAE, defining and establishing channels of communication to ensure harmonisation in the decision-making process and prevent duplication of information for the patient | 5 | 4,5 |
| 5.2 Promote initiatives in collaboration with Patient Associations to make known the role of the hospital pharmacist in managing HAE patients | 5 | 4,5 |
| 5.3 Promoting the use of telepharmacy tools for patient health education and training as a complement to in-person appointments | 5 | 4,5 |
| 7.3 From the Spanish Society of Hospital Pharmacy, promote training programmes among hospital pharmacists in the management of HAE patients | 5 | 4,5 |
| 7.4 Promote training programmes among healthcare professionals in patient training and communication techniques. | 5 | 4,5 |
| 4.2 Have a designated pharmacist knowledgeable about the pathology and promote visibility initiatives for the pharmacist’s role within the hospital as part of the multidisciplinary team responsible for managing HAE patients | 5 | 4,1 |
HAE, hereditary angioedema.